Citigroup Maintains Buy on Advanced Energy Indus, Raises Price Target to $114
Citigroup analyst Atif Malik maintains Advanced Energy Indus (NASDAQ:AEIS) with a Buy and raises the price target from $95 to $114.
Needham Maintains Buy on Advanced Energy Indus, Raises Price Target to $88
Needham analyst Quinn Bolton maintains Advanced Energy Indus (NASDAQ:AEIS) with a Buy and raises the price target from $80 to $88.
Raymond James Maintains Outperform on Advanced Energy Indus, Lowers Price Target to $100
Raymond James analyst Pavel Molchanov maintains Advanced Energy Indus (NASDAQ:AEIS) with a Outperform and lowers the price target from $112 to $100.
Loop Capital Initiates Coverage On Advanced Energy Indus with Hold Rating, Announces Price Target of $78
Loop Capital analyst Scott Graham initiates coverage on Advanced Energy Indus (NASDAQ:AEIS) with a Hold rating and announces Price Target of $78.
Advanced Energy Indus’s Return on Invested Capital Insights
According to Benzinga Pro data Advanced Energy Indus (NASDAQ:AEIS) posted a 7.23% decrease in earnings from Q4. Sales, however, increased by 0.13% over the previous quarter to $397.46 million.
Needham Maintains Buy on Advanced Energy Indus, Lowers Price Target to $100
Needham analyst Quinn Bolton maintains Advanced Energy Indus (NASDAQ:AEIS) with a Buy and lowers the price target from $120 to $100.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.